Discovery of natural product derivative triptolidiol as a direct NLRP3 inhibitor by reducing K63‐specific ubiquitination
British Journal of Pharmacology · 2025-10 · 182 (20) · 4876-4893
DOI: 10.1111/bph.17320 ↗At a glance
Journal article in British Journal of Pharmacology, 2024-09. Written by Mo-Yu Ding and 5 co-authors. Institution: Institute of Chinese Medical Sciences and State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Macao SAR, China. Major MEDLINE topics: Biological Products, NLR Family, Pyrin Domain-Containing 3 Protein, Anti-Inflammatory Agents, Non-Steroidal, Diterpenes. Cited 12 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Shenzhen Science, Technology and Innovation Commission, Innovative Team of Universities in Guangdong Province, Science and Technology Development Fund Macau.
Abstract (original language)
Background and Purpose NLRP3 is up‐regulated in inflammatory and autoimmune diseases. The development of NLRP3 inhibitors is challenged by the identification of compounds with distinct mechanisms of action avoiding side effects and toxicity. Triptolide is a natural product with multiple anti‐inflammatory activities, but a narrow therapeutic window. Experimental Approach Natural product triptolide derivatives were screened for NLRP3 inhibitors in human THP‐1 and mouse bone marrow‐derived macrophages. The efficacy of potent NLRP3 inhibitors was evaluated in LPS‐induced acute lung injury and septic shock models. Key Results Triptolidiol was identified as a selective inhibitor of NLRP3 with high potency. Triptolidiol inactivated the NLRP3 inflammasome in human THP‐1 and mouse primary macrophages primed with LPS. Triptolidiol specifically inhibited pro‐caspase 1 cleavage downstream of NLRP3, but not AIM2 or NLRC4 inflammasomes. Based on the structure–activity relationship study, the C8‐β‐OH group was critical for its binding to NLRP3. Triptolidiol exhibited a submicromolar K D for NLRP3, binding to residue C280. This binding prevented the interaction of NLRP3 with NEK7, the key regulator of NLRP3 inflammasome oligomerization and assembly, but not with the inflammasome adaptor protein ASC. Triptolidiol decreased the K63‐specific ubiquitination of NLRP3, leading NLRP3 to a “closed” inactive conformation. Intraperitoneal administration of triptolidiol significantly attenuated LPS‐induced acute lung injury and lethal septic shock. Conclusion and Implications Triptolidiol is a novel NLRP3 inhibitor that regulates inflammasome assembly and activation by decreasing K63‐linked ubiquitination. Triptolidiol has novel structural features that make it distinct from reported NLRP3 inhibitors and represents a viable therapeutic lead for inflammatory diseases. LINKED ARTICLES This article is part of a themed issue Drugs and Drug Targets in Metabolic and Chronic Inflammatory Diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.20/issuetoc
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute of Chinese Medical Sciences and State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Macao SAR, China.
- SUSTech Academy for Advanced Interdisciplinary Studies and Department of Chemistry, and Shenzhen Grubbs Institute, Southern University of Science and Technology, Shenzhen, China.
- Department of Pharmaceutical Sciences, Faculty of Health Science, University of Macau, Macao SAR, China.
- Minister of Education Science Center for Precision Oncology, University of Macau, Macao SAR, China.
ORCID profiles: Mo-Yu Ding, Chengqing Ning, Shao-Ru Chen, Hao-Ran Yin, Jing Xu, Ying Wang
Funding
- Shenzhen Science, Technology and Innovation Commission
- Innovative Team of Universities in Guangdong Province
- Science and Technology Development Fund Macau
- Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis
- Education Department of Guangdong Province, Key research projects in colleges and universities in Guangdong Province
- Shenzhen-Hong Kong-Macao Science and Technology Innovation Project (Category C)
- Science, Technology and Innovation Commission of Shenzhen Municipality
Cite
APA
Ding, M. Y., Ning, C., Chen, S. R., Yin, H. R., Xu, J., & Wang, Y. (2025). Discovery of natural product derivative triptolidiol as a direct NLRP3 inhibitor by reducing K63‐specific ubiquitination. British Journal of Pharmacology, 182(20), 4876-4893. https://doi.org/10.1111/bph.17320
Vancouver
Ding MY, Ning C, Chen SR, Yin HR, Xu J, Wang Y. Discovery of natural product derivative triptolidiol as a direct NLRP3 inhibitor by reducing K63‐specific ubiquitination. British Journal of Pharmacology. 2025;182(20):4876-4893. doi:10.1111/bph.17320
BibTeX
@article{Ding2025,
author = {Ding, Mo-Yu and Ning, Chengqing and Chen, Shao-Ru and Yin, Hao-Ran and Xu, Jing and Wang, Ying},
title = {Discovery of natural product derivative triptolidiol as a direct NLRP3 inhibitor by reducing K63‐specific ubiquitination},
journal = {British Journal of Pharmacology},
year = {2025},
volume = {182},
number = {20},
pages = {4876--4893},
doi = {10.1111/bph.17320}
}
EUVIMED